GlassScriptPhysician profile
Jeffery Gryn
NPI 1427033455
$588.87
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $47.25.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $44.71 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $36.72 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.30 | 2019 | |
| Astellas Pharma US INC | $34.04 | 2019 | |
| Genentech USA, INC. | $27.54 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.29 | 2019 | |
| Rigel Pharmaceuticals, INC. | $24.81 | 2019-2020 | |
| Emd Serono, INC. | $23.77 | 2019 | |
| Daiichi Sankyo INC. | $22.86 | 2019 | |
| Nevro Corp. | $21.20 | 2020 | |
| Alexion Pharmaceuticals, INC. | $20.95 | 2019 | |
| Celgene Corporation | $19.48 | 2019 | |
| Eisai INC. | $17.11 | 2019 | |
| Array Biopharma INC | $16.92 | 2019 | |
| Exelixis INC. | $16.65 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.53 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $15.94 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $15.90 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.62 | 2019 | |
| Lilly USA, LLC | $15.61 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.55 | 2019 | |
| Seagen INC. | $14.68 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.35 | 2019 | |
| Genzyme Corporation | $12.79 | 2019 | |
| Janssen Biotech, INC. | $12.78 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.04 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $11.13 | 2019 | |
| Clovis Oncology, INC. | $11.02 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffery Gryn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.